Weight loss drug Liraglutide may slow the worsening of Alzheimer’s disease. It has been reported to reduce brain volume loss by almost 50% in people with Alzheimer’s disease MedicalXpress.
Liraglutide is part of the group of GLP-1 agonists that includes the semaglutide-based drugs Vegovi and Ozempic. They were developed to treat type 2 diabetes, but they have also revolutionized the treatment of obesity.
The new study involved 200 patients with Alzheimer’s disease. Liraglutide significantly slowed the loss of brain tissue and mental abilities compared to a dummy drug (placebo). The drug protected areas of the brain that control memory, learning, language and decision-making. After one year of treatment, the deterioration in these functions slowed by 18%. Brain volume loss was 50% less than in the placebo group.
The exact mechanism of action of liraglutide is unknown. Scientists believe it may protect the brain by reducing inflammation or increasing the cells’ sensitivity to insulin. It may also increase nerve cells’ resistance to the effects of Alzheimer’s disease or improve communication between nerve cells in the brain.
Liraglutide and its analogues are already approved for the treatment of obesity and diabetes, so their repurposing in patients with dementia could be rapid. Results from the new phase of testing are due by the end of 2025.
Previously in olive to create a substance that lowers sugar levels and helps you lose weight.